Cadrenal Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-07-15.
Cadrenal Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on July 15, 2026. The filing reports $8.84M sold. Its industry group is Biotechnology. It names Quang Pham (Chairman of the Board and Chief Executive Officer), John Sharp (Interim Chief Financial Officer), James Ferguson (Chief Medical Officer) (SEC Form D, July 15, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Cadrenal Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-07-15 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Cadrenal Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Cadrenal Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Florida, filed within 90 days of this one, largest first.
Get an email when Cadrenal Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Cadrenal Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Cadrenal Therapeutics, Inc. →Get the full cited report on Cadrenal Therapeutics, Inc.
What the filing shows about Cadrenal Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cadrenal Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Cadrenal Therapeutics, Inc.'s address as 822 A1A North, Suite 306, Ponte Vedra, FL 32082.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Cadrenal Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Cadrenal Therapeutics, Inc. See pricing
Cadrenal Therapeutics, Inc. is a registered filer with the SEC (CIK 1937993) and has filed since 2022-12-08. 6 filings are on record, the latest on 2026-07-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Cadrenal Therapeutics, Inc.'s Form D of 2026-07-15 names Quang Pham, John Sharp, James Ferguson and 4 more as its officers, directors or promoters.
Its new offerings report $38.34M sold across 6 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $8.84M, on the same scale — one filing against the whole group's total, so it sits low by construction.
While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.
Checked away from the filing. What is below does not come from the record on sec.gov.
Cadrenal Therapeutics is developing novel and differentiated biopharmaceutical products that bridge critical gaps in current acute and chronic anticoagulant therapy.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer, Director.
Quang Pham is named as Chairman of the Board and Chief Executive Officer on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
On the filing as: Executive Officer.
John Sharp is named as Interim Chief Financial Officer on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
On the filing as: Executive Officer.
James Ferguson is named as Chief Medical Officer on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
On the filing as: Executive Officer.
Jeffrey Cole is named as Chief Operating Officer on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
Lee Golden is named as Director on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
John Murphy is named as Director on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
Glynn Wilson is named as Director on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
7 people named on the filing — 4 holding an executive role and 3 as directors only.
Named as of the 2026-07-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Cadrenal Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cadrenal Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cadrenal Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Cadrenal Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Cadrenal Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (cadrenal.com).
Each opens in a new tab, filled in for Cadrenal Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: The rest of the US raises, week of 2026-07-13 · Biotech raises, week of 2026-07-13
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/cadrenal-therapeutics-inc-form-d-26078373